erythropoiesis-stimulating agent


Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.

erythropoiesis-stimulating agent

Abbreviation: ESA.
Any drug that binds to cellular receptors for erythropoietin and encourages red blood cell production by the bone marrow. Members of this class of drugs, which include epoietin and darbopoietin, are used to treat anemia, e.g., in patients with chronic kidney disease, cancer, or aplastic anemia. ESAs are used as an alternative to red blood cell transfusions. Potential side effects of treatment include high blood pressure and an increased risk of blood clots.
See also: agent
References in periodicals archive ?
The erythropoiesis-stimulating agents (ESAs) epoetin alfa and darbepoetin are indicated for the treatment of anemia caused by end-stage renal disease (ESRD), zidovudine therapy in patients with HIV, chemotherapy in cancer patients, and also to reduce transfusion need in patients scheduled for non-cardiac major surgery.
The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: A tale of two receptors.
Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: Overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Epoetin beta and the other currently available erythropoiesis-stimulating agents are produced by a complex manufacturing process.
They were both assessed for and demonstrated good understanding of anemia in CKD and all of its ramifications, including erythropoiesis-stimulating agent (ESA) therapy.
The companies added OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the US.
Patients on hemodialysis with a below-target hemoglobin (Hb) level, despite receiving an erythropoiesis-stimulating agent (ESA), are an issue of increasing concern because anemia is associated with poor outcomes in this population.
According to the company, OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the US.
The article, titled "Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients," was published online in the American Journal of Kidney Diseases.
The companies added OMONTYS (peginesatide) Injection is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia to be made available to the dialysis patient population in the US.
A larger dose of IV iron, such as 1 gram administered over a few weeks, can replenish storage iron in the reticuloendothelial system, increase hemoglobin (Hb) levels, and lower erythropoiesis-stimulating agent (ESA) requirements (Coyne et al., 2007; Kapoian et al., 2008).

Full browser ?